Non-Cystic Fibrosis Bronchiectasis (NCFB) Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of NCFB Therapeutics | DelveInsight

DelveInsight's Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Insight 2026 report provides comprehensive global coverage of available and pipeline therapies for Non-Cystic Fibrosis Bronchiectasis across various stages of clinical and nonclinical development. The report covers 12+ companies and 15+ pipeline drugs, providing insights into emerging therapies, clinical trial activities, therapeutic assessments, and pipeline development activities in the NCFB treatment landscape.

Key takeaways from the Non-Cystic Fibrosis Bronchiectasis (NCFB) Clinical Trial Landscape Report

• DelveInsight's NCFB pipeline report depicts a developing space with 12+ companies working to develop 15+ pipeline therapies for Non-Cystic Fibrosis Bronchiectasis treatment.
• Key NCFB companies such as Haisco Pharmaceutical Group Co., Ltd., CSL Limited, UCB S.A., S-INFINITY Pharmaceuticals Co., Ltd., Reistone Biopharma Company Limited, and others are involved in developing therapies for the indication.
• Promising NCFB pipeline therapies in various stages of development include HSK31858, CSL787, Galvokimig, XH-S004, RSS0343, and others.
• The pipeline includes Phase III, Phase II, Phase I, preclinical, discovery, discontinued, and inactive candidates, reflecting a diverse therapeutic development landscape.
• Haisco Pharmaceutical Group Co., Ltd. has a candidate, HSK31858, in the most advanced stage, Phase III.

Request a sample and discover the recent advances in Non-Cystic Fibrosis Bronchiectasis treatment drugs:
https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Non-Cystic Fibrosis Bronchiectasis (NCFB)?

Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic, progressive lung disease characterized by permanent and abnormal dilation of the bronchi. This structural damage leads to impaired mucociliary transport, chronic airway infection, and persistent inflammation. Unlike cystic fibrosis, NCFB is a heterogeneous condition that can result from various infectious, inflammatory, immune-related, and airway-clearance abnormalities.
NCFB most frequently affects older adults and is associated with increased morbidity and reduced quality of life. The hallmark symptoms include a persistent daily cough and chronic mucus production. Patients may also experience chest pain, shortness of breath, wheezing, fatigue, recurrent fever or chills, and, in some cases, hemoptysis.
The disease is driven by a self-perpetuating cycle involving impaired mucociliary clearance, chronic infection, and persistent inflammation. Accumulation of mucus allows pathogens to persist and triggers predominantly neutrophilic inflammation. The resulting inflammatory mediators and proteolytic enzymes progressively damage the bronchial walls, causing irreversible airway dilation and further impairment of mucus clearance.
NCFB may arise from a wide range of underlying conditions, including autoimmune diseases, immunodeficiency disorders, abnormalities of ciliary function, allergic bronchopulmonary aspergillosis, chronic pulmonary aspiration, COPD, alpha-1 antitrypsin deficiency, inflammatory bowel diseases, and recurrent or severe respiratory infections such as pneumonia, pertussis, tuberculosis, and fungal infections.
Diagnosis generally involves clinical evaluation, medical and family history, blood testing, imaging, lung function testing, and sputum cultures. High-resolution CT is the most common and definitive imaging method used to confirm bronchiectasis. Management focuses on controlling symptoms, preventing recurrent infections and exacerbations, improving mucus clearance, and addressing underlying conditions. Treatment may include antibiotics, inhaled therapies, hydration, chest physiotherapy, oxygen therapy when required, and surgery in selected severe cases.

Emerging Non-Cystic Fibrosis Bronchiectasis Drug Profiles

HSK31858: Haisco Pharmaceutical Group Co., Ltd.
HSK31858 is a novel, oral, irreversible dipeptidyl peptidase-1 (DPP-1) inhibitor being developed by Haisco Pharmaceutical Group for neutrophil-mediated chronic inflammatory diseases, particularly Non-Cystic Fibrosis Bronchiectasis. The therapy is designed to reduce neutrophil-driven inflammation and potentially decrease disease exacerbations. HSK31858 is currently being evaluated in Phase III development for NCFB.

CSL787: CSL Behring
CSL787 is a novel, nebulized 10% human plasma-derived polyvalent immunoglobulin G (IgG) solution being developed by CSL Behring for chronic lung infections, specifically in patients with Non-Cystic Fibrosis Bronchiectasis. The therapy uses a customized vibrating-mesh nebulizer for targeted, non-invasive delivery of IgG directly to the airways. CSL787 is currently being evaluated in Phase II development for NCFB.

Galvokimig: UCB S.A.
Galvokimig is a multispecific antibody-based therapeutic designed to inhibit IL-13, IL-17A, and IL-17F, while incorporating albumin binding to modulate its serum half-life. These cytokines are key mediators of inflammation and represent distinct inflammatory pathways. Galvokimig is currently being evaluated in Phase II development for Non-Cystic Fibrosis Bronchiectasis.

Learn more about the novel and emerging Non-Cystic Fibrosis Bronchiectasis pipeline therapies:
https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery, Discontinued & Inactive
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key NCFB Companies: Haisco Pharmaceutical Group Co., Ltd., CSL Limited, UCB S.A., S-INFINITY Pharmaceuticals Co., Ltd., Reistone Biopharma Company Limited, and others
• Key NCFB Pipeline Therapies: HSK31858, CSL787, Galvokimig, XH-S004, RSS0343, and others.

Dive deep into rich insights for new drugs for Non-Cystic Fibrosis Bronchiectasis treatment, visit:
https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Report Introduction
2. Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Report Executive Summary
3. Non-Cystic Fibrosis Bronchiectasis (NCFB): Overview
4. Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Therapeutics
5. Non-Cystic Fibrosis Bronchiectasis (NCFB) Therapeutic Assessment
6. Non-Cystic Fibrosis Bronchiectasis (NCFB) - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. Preclinical and Discovery Stage Products
11. Inactive Products
12. Non-Cystic Fibrosis Bronchiectasis (NCFB) Key Companies
13. Non-Cystic Fibrosis Bronchiectasis (NCFB) Key Products
14. Non-Cystic Fibrosis Bronchiectasis (NCFB) - Unmet Needs
15. Non-Cystic Fibrosis Bronchiectasis (NCFB) - Market Drivers and Barriers
16. Non-Cystic Fibrosis Bronchiectasis (NCFB) - Future Perspectives and Conclusion
17. Non-Cystic Fibrosis Bronchiectasis (NCFB) Analyst Views
18. Non-Cystic Fibrosis Bronchiectasis (NCFB) Key Companies
19. Appendix

For further information on the Non-Cystic Fibrosis Bronchiectasis pipeline therapeutics, reach out:
https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

This release was published on openPR.